Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse.

نویسندگان

  • Kaori Okayasu
  • Yuichiro Takeda
  • Jun Kojima
  • Atsuto Yoshizawa
  • Nobuyuki Kobayashi
  • Haruhito Sugiyama
  • Koichiro Kudo
چکیده

A 44-year-old man was treated with amiodarone for dilated cardiomyopathy. After 53 months, he developed amiodarone-induced interstitial pneumonia. Amiodarone treatment was terminated, and the patient was given corticosteroids. These treatments were effective. However, pneumonitis recurred whenever prednisolone was reduced to less than 5 mg per day. Considering the patient's background characteristics, we considered his body mass index (BMI, kg/m(2)) and found his to be high. When four additional patients with amiodarone pulmonary toxicity were reviewed at our institute, a correlation between BMI and the duration of shadow disappearance was found (R(2)=0.8695). Because amiodarone is lipophilic, the patient's high BMI might have influenced the repeated appearance of pulmonary toxicity.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Amiodarone toxicity: recurrence of interstitial pneumonitis after withdrawal of the drug.

Amiodarone hydrochloride, an iodinated benzofuran derivative, is effective for treatment of supraventricular and ventricular arrhythmias. Pulmonary fibrosis has been reported after treatment with this drug. We present a patient with amiodarone pulmonary toxicity, who initially responded to corticosteroid therapy, but who developed a clinical relapse two months after withdrawal of the drug.

متن کامل

Pulmonary toxicity in patients receiving low-dose amiodarone.

RATIONALE Although there have been reports of pulmonary toxicity with low-dose amiodarone, it is generally believed that low-dose therapy is safe. METHODS The clinical data for eight patients identified from a retrospective chart review are presented. RESULTS All of the patients were receiving amiodarone, 200 mg/d, for an average of 2 years. The average age was 77 years (range, 65 to 89 yea...

متن کامل

Protective Effect of Caffeic Acid Phenethyl Ester (CAPE) on Amiodarone-Induced Pulmonary Fibrosis in Rat

Treatment with amiodarone, a commonly prescribed antidysrhythmic agent, is associated with pulmonary fibrosis (PF) which is a commonly progressive and untreatable dieases. Caffeic acid phenethyl ester (CAPE) is a phenolic antioxidant and an active anti-inflammatory, anticancer, antimicrobial and antioxidant component of propolis (bee glue; a resinous hive product collected by honey bees). In th...

متن کامل

Clinical features of amiodarone-induced pulmonary toxicity.

The incidence and clinical predictors of amiodarone pulmonary toxicity were examined in 573 patients treated with amiodarone for recurrent ventricular (456 patients) or supraventricular (117 patients) tachyarrhythmias. Amiodarone pulmonary toxicity was diagnosed in 33 of the 573 patients (5.8%), based on symptoms and new chest radiographic abnormalities (32 of 33 patients) and supported by abno...

متن کامل

Amiodarone and Pulmonary Toxicity 06

Cyclophosphamide is a chemotherapeutic agent with the potential to cause pulmonary toxicity, most commonly in the form of diffuse alveolar damage. Cyclophosphamide-induced pulmonary toxicity is extremely rare and often difficult to recognize because of presence of confounding factors, including use of other cytotoxic drugs, radiation pneumonitis, oxygen toxicity, pulmonary infections, and malig...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Internal medicine

دوره 45 22  شماره 

صفحات  -

تاریخ انتشار 2006